Jeff Jonker

Jeff Jonker is a veteran biotech executive with experience in operational, strategic, business development, and legal roles across public and private companies. Mr. Jonker is a senior advisor to Ambys Medicines, where he was previously President and CEO, and other early-stage biotech companies. Immediately prior to Ambys, Mr. Jonker served as President of NGM Biopharmaceuticals (NASDAQ: NGM), where he established the Merck partnership, grew the organization into a fully integrated clinical development company, and guided the company’s robust pipeline, including therapeutics for immuno-oncology, retinal, liver and metabolic diseases. Prior to joining NGM, Mr. Jonker was Senior Vice President, Corporate and Business Development at Theravance Biopharma (NASDAQ: TBPH) and held that same role at Theravance, Inc. (NASDAQ: THRX) prior to completing the spin-out of TBPH and creation of Innoviva, Inc. (NASDAQ: INVA). He previously served as Chief Business Officer of Satori Pharmaceuticals, Vice President of Business Development and Corporate Strategy for Gloucester Pharmaceuticals prior to its acquisition by Celgene (NASDAQ: CELG), and in multiple leadership positions in the business development and legal groups at Genentech. Prior to Genentech, Mr. Jonker was a member of the Technology Transactions Group at Wilson, Sonsini, Goodrich & Rosati, representing clients in the life science and high tech industries. Mr. Jonker holds a J.D. from Columbia University School of Law, an M.LITT. from the University of St. Andrews, and a B.A. from Claremont McKenna College.